GSAS Harvard Biotech Club x Roivant Sciences
US Healthcare & Drug Pricing Debate
Earlier this month, nearly 30 pharmaceutical companies announced that they have taken steps to raise the U.S. prices of their medications. Why can’t government health agencies negotiate or directly regulate drug prices in the world’s most expensive pharmaceutical market?
Come hear the thoughts of health care experts. Ask questions on current policies. We will have catering and an open bar for the reception after the event!
We invite you to join us on:
February 22, 5:30-6:30 PM
Science Center, Hall B
Harvard Main Campus
Followed by a 1 hour reception
Joining us for this special event:
Peter Kolchinsky, Ph.D.
Co-founder, Portfolio Manager, & Managing Director, RA Capital Management, LLC
Peter Kolchinsky is co-founder, Managing Director, and Portfolio Manager of RA Capital Management, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves as a member of the Board of Directors for a number of private companies. He is the author of “The Entrepreneur’s Guide to a Biotech Start-up” and the Biotech Social Contract series.
Policy advisor and political strategist
Avik Roy served as policy advisor to Mitt Romney’s 2012 presidential campaign and senior advisor to both Rick Perry’s and Marco Rubio’s 2016 presidential campaigns. Roy’s financial and medical background, along with his experience on presidential campaigns, makes him a frequent guest on cable news networks such as Fox News, Fox Business, MSNBC, CNBC and Bloomberg Television. He has appeared on PBS’s Newshour and on HBO’s Real Time With Bill Maher.
Founder & CEO, Roivant Sciences
Vivek Ramaswamy is an American entrepreneur in the biotechnology sector. He is the founder and CEO of the pharmaceutical company Roivant Sciences, founded in 2014 and now valued at $7 billion. Ramaswamy seeks to unlock innovation in drug discovery and commercialization by reducing the time and cost of the drug development process.